A new anti-idiotype antibody capable of binding rituximab on the surface of lymphoma cells

Blood

Volumn 104, Issue 8, 2004, Pages 2540-2542

  Cragg, Mark S ^a   Bayne, Mike B ^b   Tutt, Alison L ^b   French, Ruth R ^b   Beers, Stephen ^b   Glennie, Martin J ^b   Illidge, Timothy M ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CD20 ANTIGEN; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; RITUXIMAB;

ANTIBODY SPECIFICITY; ANTIGEN BINDING; ARTICLE; B LYMPHOCYTE; BINDING AFFINITY; CELL SURFACE; CONTROLLED STUDY; DRUG BINDING; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LYMPHOMA CELL; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL;

EID: 4944220440     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-05-1733     Document Type: Article

References (23)

1. Coiffier B. Monoclonal antibodies combined to chemotherapy for the treatment of patients with lymphoma. Blood Rev. 2003;17:25-31.
2. Dillman RO. Treatment of low-grade B-cell lymphoma with the monoclonal antibody rituximab. Semin Oncol. 2003;30:434-447.
3. Johnson P, Glennie M. The mechanisms of action of rituximab in the elimination of tumor cells. Semin Oncol. 2003;30:3-8.
4. Maloney DG. Rituximab for follicular lymphoma. Curr Hematol Rep. 2003;2:13-22.
5. Boye J, Elter T, Engert A. An overview of the current clinical use of the anti-CD20 monoclonal antibody rituximab. Ann Oncol. 2003;14:520-535.
6. Anolik J, Sanz I, Looney RJ. B cell depletion therapy in systemic lupus erythematosus. Curr Rheumatol Rep. 2003;5:350-356.
7. Bosly A, Keating MJ, Stasi R, Bradstock K. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma. Anticancer Drugs. 2002;13(suppl 2): S25-S33.
8. Cohen Y, Nagler A. Treatment of refractory autoimmune diseases with ablative immunotherapy. Autoimmun Rev. 2004;3:21-29.
9. Anolik JH, Campbell D, Felgar RE, et al. The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus. Arthritis Rheum. 2003;48:455-459.
10. Byrd JC, Kitada S, Flinn IW, et al. The mechanism of tumor cell clearance by rituximab in vivo in patients with B-cell chronic lymphocytic leukemia: evidence of caspase activation and apoptosis induction. Blood. 2002;99:1038-1043.
11. Cerny T, Borisch B, Introna M, Johnson P, Rose AL. Mechanism of action of rituximab. Anticancer Drugs. 2002;13(suppl 2):S3-S10.
12. Cragg MS, Glennie MJ. Antibody specificity controls in vivo effector mechanisms of anti-CD20 reagents. Blood. 2004;103:2738-2743.
13. Di Gaetano N, Cittera E, Nota R, et al. Complement activation determines the therapeutic activity of rituximab in vivo. J Immunol. 2003;171: 1581-1587.
14. Maloney DG. Mechanism of action of rituximab. Anticancer Drugs. 2001;12(suppl 2):S1-S4.
15. Smith MR. Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance. Oncogene. 2003;22:7359-7368.
16. Berinstein NL, Grillo-Lopez AJ, White CA, et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol. 1998;9:995-1001.
17. Iacona I, Lazzarino M, Avanzini MA, et al. Rituximab (IDEC-C2B8): validation of a sensitive enzyme-linked immunoassay applied to a clinical pharmacokinetic study. Ther Drug Monit. 2000; 22:295-301.
18. Jilani I, O'Brien S, Manshuri T, et al. Transient down-modulation of CD20 by rituximab in patients with chronic lymphocytic leukemia. Blood. 2003;102:3514-3520.
19. Glennie MJ, McBride HM, Worth AT, Stevenson GT. Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments. J Immunol. 1987; 139:2367-2375.
20. Tutt AL, French RR, Illidge TM, et al. Monoclonal antibody therapy of B cell lymphoma: signaling activity on tumor cells appears more important than recruitment of effectors. J Immunol. 1998; 161:3176-3185.
21. Teeling JL, French, RR, Cragg MS, et al. Characterisation of new human CD20 monoclonal antibodies with potent cytolytic activity against non-Hodgkin's lymphomas. Blood. Prepublished on June 1, 2004, as DOI 10.1182/blood-2004-01- 0039.
22. Johnstone RW, Andrew SM, Hogarth MP, Pietersz GA, McKenzie IF. The effect of temperature on the binding kinetics and equilibrium constants of monoclonal antibodies to cell surface antigens. Mol Immunol. 1990;27:327-333.
23. Mason D, Williams A. Kinetics of antibody reactions and the analysis of cell surface antigens. In: Weir D, ed. Handbook of Experimental Immunology. Vol 1. Blackwells Scientific Publications; 1986.